US FDA Sets User Fees For FY2021
Coronavirus Only Mentioned As Part Of PDUFA Calculation
Executive Summary
ANDA submission rate increases, while the NDA and BLA fee drops and the biosimilar fee is unchanged.
You may also be interested in...
US FDA’s Coronavirus Workload Shifting Beyond Idea Stage
Pre-IND inquiries are slowing and the FDA says more late-stage development work is coming.
Virtual Adcom Vet Says In-Person Events May Be Better For Product Approval Recommendations
Syndax CEO also says US FDA’s virtual meetings would benefit from having advisory committee members on camera, which may be a technology challenge.
Seven Days In March: NDA-BLA and ANDA Approval Output Diverged As Coronavirus Teleworking Began
New drug approvals dropped, likely because of a new focus on COVID-19 treatments, while generic drug approvals increased.